Big Pharma Split (TSX:PRM) Shareholder Yield % : -12.28% (As of Dec. 2025)


TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split Shareholder Yield %?

Big Pharma Split TSX:PRM 7 Shareholder Yield % is -12.28% as of Dec. 2025. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Big Pharma Split's Shareholder Yield % was -12.28%.


Big Pharma Split  (TSX:PRM) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Big Pharma Split Shareholder Yield % Related Terms


Big Pharma Split Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Big Pharma Split's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Big Pharma Split Shareholder Yield % Chart

Big Pharma Split Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only -26.31 6.35 42.25 10.29 -11.45

Big Pharma Split Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.25 14.04 10.29 9.51 -11.45

TSX:PRM vs BLK, BX, KKR: Shareholder Yield % Comparison

For the Asset Management subindustry, Big Pharma Split's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Big Pharma Split Shareholder Yield % vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Shareholder Yield % falls into.


TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split Shareholder Yield % Calculation

Big Pharma Split's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-11.45 %+0 %
=-11.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -12.28% mean?
Big Pharma Split (TSX:PRM) has a Shareholder Yield % of -12.28% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's Shareholder Yield % too high?
Big Pharma Split's current Shareholder Yield % is -12.28%. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Shareholder Yield % compare to BLK and BX?
Big Pharma Split's Shareholder Yield % of -12.28% can be compared against companies in the Asset Management industry. The industry median Shareholder Yield % is 4.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for an Asset Management company?
The median Shareholder Yield % among Asset Management companies is 4.22, based on 1,473 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median Shareholder Yield % is 4.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current Shareholder Yield % is -12.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Shareholder Yield % of -12.28%. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Shareholder Yield % is -12.28%. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Shareholder Yield % is -12.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • Shareholder Yield %: -12.28%
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value